Cambridge investigators zero in on a new, niche drug target for lung cancer
Lung cancer has one of the poorest survival rates in oncology. A group of researchers at the University of Cambridge wants to change that.
Homing in on lung squamous cell carcinoma (LUSC) — a common subtype of non-small cell lung cancer — the scientists found that targeting an epigenetic regulator called SETD8 can potentially lead to the selective inhibition of LUSC cell growth. That’s because SETD8 inhibition helps disrupt the actions of BCL11A, an oncogene responsible for a protein found in high amounts in LUSC cells.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
